DIRAS1

DIRAS1 is a small GTPase that acts as a tumor suppressor by restraining oncogenic signaling and promoting autophagy-mediated cancer cell death (PMID:29368982, PMID:26814130). Mechanistically, it binds SmgGDS, a noncanonical guanine nucleotide exchange factor, but is not itself a substrate for SmgGDS-mediated GDP/GTP exchange; instead it functions as a dominant-negative-like competitor that blocks SmgGDS engagement of the oncogenic GTPases K-Ras4B, RhoA, and Rap1A and thereby suppresses RhoA- and SmgGDS-driven NF-κB transcriptional activity (PMID:26814130). Downstream, re-expressed DIRAS1 inhibits AKT1-MTOR and RAS-MAPK signaling and drives nuclear accumulation of the autophagy transcription factors FOXO3 and TFEB to induce autophagic cell death (PMID:29368982), and in osteosarcoma it suppresses ERK phosphorylation selectively without affecting AKT (PMID:35413492). In the nervous system, DIRAS1 promotes neurite outgrowth and axon guidance through a Rac1-dependent pathway requiring an intact C-terminus, elevating Rac1 activity while downregulating RhoA and acting via Pak1, CDK5, and Arp2/3 (PMID:26635085). DIRAS1 expression is silenced by layered epigenetic control — promoter hypermethylation and histone deacetylation (PMID:34680261) and m6A modification written by METTL3/METTL14 and erased by FTO/ALKBH5 that tunes mRNA stability and translation efficiency (PMID:35413492, PMID:38372700) — and its restoration sensitizes glioblastoma cells to lomustine through a p53-dependent DNA damage response (PMID:34680261). In a context-dependent reversal, DIRAS1 can also promote oxaliplatin resistance in colorectal cancer by upregulating PHB1 to maintain mitochondrial stability (PMID:40723377).

1. 2015 Medium

   Established that DIRAS1 has a developmental signaling function in neurons, acting upstream of the Rac1/RhoA balance to drive neurite outgrowth, rather than being a purely tumor-associated gene.

   Evidence Overexpression and morpholino knockdown with mRNA rescue in zebrafish plus GST pull-down for Rac1 activity and pharmacological inhibition in Neuro-2a cells

   PMID:26635085

   Open questions at the time

   • Direct biochemical mechanism by which DIRAS1 elevates Rac1 activity is not resolved
   • Findings rest on a zebrafish ortholog and a neuronal cell line, not human neurons
   • Whether the same Rac1 axis operates in non-neuronal contexts is untested
2. 2016 High

   Defined the core molecular mechanism: DIRAS1 is not an exchange substrate but a competitive inhibitor that sequesters SmgGDS away from oncogenic GTPases, explaining how it can dampen RhoA/NF-κB output.

   Evidence Co-immunoprecipitation, in silico docking, GDP/GTP exchange assay, competitive binding, and NF-κB reporter assays in HEK293T and cancer cell lines

   PMID:26814130

   Open questions at the time

   • Structural basis of the DIRAS1-SmgGDS interface not determined experimentally
   • Nucleotide-loading state of DIRAS1 in cells and its upstream regulators unknown
   • Endogenous (non-overexpression) competition with K-Ras4B/RhoA/Rap1A not quantified
3. 2018 Medium

   Connected DIRAS1 re-expression to a defined tumor-suppressive output, showing it inhibits AKT-MTOR and RAS-MAPK signaling and engages an autophagy transcriptional program (FOXO3, TFEB) to kill cancer cells.

   Evidence Overexpression in human and murine ovarian cancer cells with western blot pathway analysis and FOXO3/TFEB nuclear localization assays

   PMID:29368982

   Open questions at the time

   • Whether autophagy induction is causal for cell death versus correlative is not dissected
   • Link between SmgGDS competition and AKT-MTOR/FOXO3/TFEB modulation not established
   • Single tumor type tested
4. 2021 Medium

   Showed that DIRAS1 is epigenetically silenced in tumors and that its restoration improves therapeutic response, framing it as a druggable suppressor.

   Evidence Glioblastoma overexpression with lomustine cytotoxicity and DNA damage assays; methylation-specific PCR; 5-azacytidine and HDAC inhibitor reactivation; and an esophageal LINC00261/miR-552-3p/DIRAS1 ceRNA radioresistance study

   PMID:34680261 PMID:34803403

   Open questions at the time

   • How DIRAS1 mechanistically promotes the p53-dependent DNA damage response is unresolved
   • ceRNA regulation provides regulation OF DIRAS1, not insight into DIRAS1 protein function
   • Reactivation drugs are not DIRAS1-specific
5. 2024 Medium

   Refined the regulatory layer by establishing m6A control of DIRAS1, with METTL3/METTL14 writers and FTO/ALKBH5 erasers setting mRNA stability and translation efficiency, and linked this to downstream ERK suppression.

   Evidence siRNA knockdown of m6A writers/erasers, pharmacological inhibitors, immunofluorescence localization, and western blot/qPCR for DIRAS1 and p-ERK in osteosarcoma and cervical cancer cells

   PMID:35413492 PMID:38372700

   Open questions at the time

   • Direct m6A sites on DIRAS1 transcript not mapped
   • Discordant mRNA-versus-protein effects of FTO inhibition not mechanistically explained
   • Reader proteins coupling m6A marks to DIRAS1 fate unidentified
6. 2025 Medium

   Demonstrated a context-dependent oncogenic role, where DIRAS1 upregulates PHB1 to stabilize mitochondria and confer oxaliplatin resistance, complicating the uniform tumor-suppressor model.

   Evidence Lentiviral knockdown/overexpression, cytotoxicity assays, transcriptomic sequencing, and in vivo xenografts with IHC in colorectal cancer

   PMID:40723377

   Open questions at the time

   • Molecular link between DIRAS1 and PHB1 upregulation not resolved
   • Reconciliation with tumor-suppressive roles in other cancers untested
   • Whether GTPase activity or SmgGDS axis is involved in PHB1 regulation unknown

• How DIRAS1's nucleotide-loading state, SmgGDS competition, and subcellular localization are mechanistically coupled to its divergent tumor-suppressive versus chemoresistance outputs remains unresolved.
• No structural or biochemical model linking SmgGDS competition to downstream AKT-MTOR/ERK/autophagy effects
• Determinants of context-dependent suppressor-versus-oncogene behavior unknown
• Endogenous upstream activators/regulators of DIRAS1 GTPase cycle uncharacterized